GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

This was the stock's third consecutive day of gains.

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

2024年12月30日，生物科技公司福泰制药（VRTX）成交额为5.82亿美元，在当日美股中排第84名，成交额较昨日增加3.89%，当日成交量为145.28万。 福泰制药（VRTX）于2024年12月30日跌2.30%，报399.35美元，该股过去5个交易日跌1.46%，整个12月跌14.69%，年初至今跌1.85%，过去52周跌1.85%。

A cognitive behavioral intervention eased chronic pain for people with kidney failure on maintenance hemodialysis, a ...

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...